Researchers reported that a senolytic therapeutic approach targeting senescent cells in the tumor microenvironment produced tumor control in preclinical pancreatic ductal adenocarcinoma (PDAC) models. The work links oncogenic KRAS biology with senescence‑associated pathways and demonstrates that clearing senescent cells can blunt tumor progression in animal studies. The study, presented by academic investigators, highlights a modality that supplements direct oncogene targeting by altering the tumor ecosystem. While promising, findings are preclinical; translation will require safety profiling, target engagement biomarkers, and demonstration of combinability with standard chemotherapy or targeted agents before human testing is feasible.